More than 106,000 deaths have already been recorded. Find out if there's a
killer in your medicine cabinet right now.‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎



<[link removed]>

August 19


 



Are you taking the #1 deadliest drug in America?

Click to See →
<[link removed]>

 






Can you guess which is the #1 deadliest drug in America?

* Beta-blockers (blood pressure drugs)
<[link removed]>
* Statins (cholesterol drugs)
<[link removed]>
* NSAIDs (arthritis drugs)
<[link removed]>
* Sleeping pills
<[link removed]>
Find out if you got the answer right:

Click here to see the #1 deadliest drug for American seniors.
<[link removed]>


<[link removed]>
--Emily

P.S. More than 106,000 deaths have already been recorded. Find out if there's
a killer in your medicine cabinetright now.
<[link removed]>
 

 





Three Stories That Could Move Markets (Ad)
Must-See: Trump’s Little-Known Plan to Save Social Security
<[link removed]>
InvestorPlace Media

Learn More →
<[link removed]>


Uncle Sam’s Portfolio Is Up 26x on the S&P 500
<[link removed]>
Weiss Ratings

Learn More →
<[link removed]>


Investing Legend Put Half His Money in This One Stock
<[link removed]>
Stansberry Research

Here’s the Ticker →
<[link removed]>








CONNOR'S HEALTH NOTES

How a Drug Death Gets Counted

Connor Hill · InsightfulWord · August 18, 2026

Numbers describing deaths caused by medication circulate constantly, they vary
by an order of magnitude between sources, and almost nobody who repeats one can
say where it came from. The variation is not because anyone is lying. It is
because at least four entirely different systems produce such figures, they
measure different things, and the results are not interchangeable.

Understanding which system produced a number is the difference between reading
a fact and reading an artifact.

The first is spontaneous adverse event reporting. The Food and Drug
Administration maintains a database into which manufacturers, clinicians and
members of the public submit reports of problems experienced by someone taking
a drug. The agency is explicit about what the resulting records are and are
not. Reports are not verified. The existence of a report does not establish
that the drug caused the event. Duplicate submissions occur. And there is no
denominator — the system records reports without knowing how many people took
the drug — so no rate can be calculated from it at all.

That last point is the one that disposes of most claims built on this data. A
count of reports, divided by nothing, cannot be compared with a count of
reports about a different drug taken by a different number of people. A widely
prescribed medication will generate more reports than a rarely prescribed one
for reasons that have nothing to do with either one's safety.

The second is death certificate coding. When a person dies, a certifier
records an underlying cause and contributing conditions, which are translated
into standardized codes and aggregated into national mortality statistics.
Adverse effects of therapeutic drugs have their own codes, but recording one
requires that the certifier recognized the connection and chose to record it —
and certifiers are frequently working without the full medication history.

The third is chart review research. Investigators read a sample of hospital
records and judge, case by case, whether a death was attributable to a
medication. This produces the most careful estimates and the smallest samples,
and it depends on reviewer judgment, which is why studies using the same method
reach different figures.The fourth is modeling. Take a rate from a chart
review, apply it to national admission or prescription volumes, and report a
projection. This produces the largest and most quotable numbers, and each of
its inputs carries the uncertainty of everything upstream.

What follows is what each system can honestly support, why attribution is
genuinely hard, and what the question is when the number matters to an
individual rather than a population.

Why Attribution Is Difficult Even Honestly

The hard part is not counting. It is deciding what caused what, in people who
typically had several conditions and several medications at once.

Consider an older adult who takes a medication, falls, fractures a hip, has
surgery, develops pneumonia during recovery, and dies. Did the drug kill them?
A reasonable case exists for recording the cause as pneumonia, as the fracture,
as the fall, or as the medication that contributed to the fall. Different
certifiers make different choices, and all of them are defensible.

Now add the counterfactual, which is the part that never appears in a
headline. The medication was prescribed for something. The relevant comparison
is not between the patient's outcome and a hypothetical patient who took
nothing and was otherwise identical. It is between the outcome with treatment
and the outcome without it, in a person who had the condition being treated.
Attribution figures count events on one side of that comparison and are silent
about the other.

There is also confounding by indication, which runs through this entire
literature. People prescribed a medication differ systematically from people
not prescribed it — they have the condition the drug treats, which is itself
associated with worse outcomes. A raw association between taking a drug and
dying is contaminated by the reason the drug was given, and separating the two
requires methods that observational death counts do not employ.


📈 Number of the Day

No denominator

The FDA's adverse event reporting system records submissions without knowing
how many people took the drug, contains unverified and duplicate reports, and
by the agency's own statement does not establish that a drug caused the
reported event. No rate can be computed from it, and counts between drugs
cannot be compared. Source: U.S. Food and Drug Administration, FAERS public
dashboard documentation.


Support or oppose: should adverse event data be public in this form?

The reporting database is open to anyone, which means unverified reports of
serious harm are searchable by the public and routinely quoted as if they were
confirmed cases. Supporters of open access argue that transparency is the
point, that researchers and journalists find genuine signals in it, and that a
regulator holding safety data privately is worse. Critics answer that
publishing unverified counts without a denominator predictably produces
misleading claims, frightens patients away from treatment, and that the same
data could be released to researchers with the caveats enforced. Should it stay
open in its current form?Hit reply — one line is enough.


What the Systems Are Good For

Dismissing all of this would be as wrong as over-reading it, and each system
has a job it does well.

Spontaneous reporting is a signal detector, and it is genuinely valuable in
that role. Its purpose is to surface rare adverse effects that clinical trials
— with a few thousand participants over a few years — could never detect. A
cluster of unusual reports about a specific drug is a reason to investigate,
and several important safety findings originated exactly this way. It generates
hypotheses. It does not test them.

Death certificate data is good at trends over time within a consistent coding
framework, which is what it was designed for. Comparing this year with last
year using the same codes is informative. Reading an absolute total as a
measure of true incidence is not.

Chart review produces the most defensible individual attributions and the
least generalizable totals, because samples are small and settings differ.

Modeled projections are useful for policy discussion about the scale of a
problem and are the least suited to any individual conclusion, because they
aggregate uncertainty at every step.

The error in almost every viral claim is using one system's output for another
system's question — most often taking a report count or a modelled projection
and presenting it as a verified death toll.


The question that actually applies to a person

Population attribution figures do not answer the question an individual is
asking, which is whether a specific medication is doing more good than harm for
them specifically. That question has a different shape and a different set of
inputs: what condition is being treated and how severe is it, what is the
individual's absolute risk from that condition, what is the absolute risk of
the relevant adverse effect at their age and with their other conditions and
medications, and does an alternative exist within the same therapeutic class
with a different profile. All four are answerable at an appointment, from the
patient's own record, in a way no national statistic can be. And the standing
caution applies without exception: stopping a prescribed medication on the
basis of any number found online, without medical advice, is dangerous for
several common classes of drug, and the risk of abrupt discontinuation is
frequently larger than the risk being avoided.


Why the Reporting System Exists at All

It would be easy to read the limitations above as an argument that spontaneous
reporting is worthless. It is not, and understanding why explains the whole
architecture of drug safety.

A clinical trial that supports approval typically enrols a few thousand
participants and follows them for a defined period. That design can detect
adverse effects occurring in perhaps one participant in a few hundred. It
cannot detect an effect occurring in one person in fifty thousand, because the
trial does not contain fifty thousand people.

Once a medication is prescribed to millions, those rare effects begin to
occur. There is no practical way to run a trial large enough to have found them
in advance, which means the only mechanism available is to watch what happens
after approval and collect reports.

That is what the reporting system is: an early warning network, deliberately
designed to be sensitive rather than specific. It is supposed to produce false
alarms, because a system tuned to avoid them would miss the genuine signals it
exists to catch.

The trade-off is that its raw output is noisy by design and was never intended
to be read as a count of confirmed harms. The agency's own caveats say so
explicitly. The failure mode is not the system. It is treating a sensitive
detector's raw output as a verdict.


What Happens When a Signal Is Real

The step that follows detection is the one that almost never appears in
content built on these numbers, and it is where the system does its actual work.

A cluster of reports triggers evaluation rather than action. Investigators
examine whether the reported events exceed what would be expected in that
population without the drug, whether a plausible biological mechanism exists,
whether the timing fits, and whether the pattern appears in other data sources
such as insurance claims or electronic health records — which, unlike the
reporting system, have denominators.

If the signal survives that scrutiny, the responses are graduated. A label may
be revised to add a warning or a contraindication. Prescribing may be
restricted to certain patients or certain settings. A study may be required as
a condition of continued marketing. In the most serious cases a product is
withdrawn.

Those actions are public and dated. Label changes are published, safety
communications are issued, and withdrawals are announced. Anyone wanting to
know whether a concern about a particular medication has been examined can look
for the regulatory record rather than the report count — and the record is the
informative document, because it represents a conclusion rather than an
allegation.


Where the Legitimate Concern Sits

None of this means medication harm is a manufactured worry. It is real, it is
substantial, and the serious version of the concern is more specific than any
total.

Adverse drug events are a well-documented cause of hospital admission in older
adults, and a substantial share of them are considered preventable. That word
is doing important work: preventable means the harm arose from a dose, an
interaction, a duration or a prescription that a review would have caught,
rather than from an unavoidable property of the drug.

The concentration is also documented. A relatively small number of drug
classes account for a large share of serious adverse events in older adults,
and the mechanisms are known — bleeding, low blood sugar, sedation and falls,
kidney injury, electrolyte disturbance. These are monitorable, which is
precisely why they are described as preventable.

That framing supports a specific and achievable response: monitoring, periodic
review of whether each prescription is still indicated, and attention to the
interactions that arise as a list lengthens. It does not support abandoning
treatment, and the people who study this most closely are the least likely to
recommend that.

The distinction between the serious version and the sensational version is
visible in what each asks the reader to do. One says have the list reviewed.
The other says be afraid of the list.


The bill, not the debate

Numbers about medication deaths circulate detached from the systems that
produced them, and the systems disagree by an order of magnitude because they
are measuring different things. The figure that applies to a household is not a
national total but an individual balance, and it is computable from a person's
own record by someone with access to it. Has anyone ever gone through your
medication list and told you what each item is protecting you from, and at what
cost?Connor Hill reads every reply.


Sources checked: U.S. Food and Drug Administration — FDA Adverse Event
Reporting System (FAERS) public dashboard and its stated limitations
<[link removed]>
·U.S. Food and Drug Administration — reporting serious problems to MedWatch
<[link removed]>
·CDC / National Center for Health Statistics — mortality data, cause-of-death
coding and classification <[link removed]> · Agency
for Healthcare Research and Quality — patient safety and adverse drug events
resources <[link removed]> · Centers for Disease Control and
Prevention — adverse drug events in adults and medication safety
<[link removed]> · American
Geriatrics Society — Beers Criteria for potentially inappropriate medication
use in older adults
<[link removed]>


Connor Hill · InsightfulWord





You’re receiving this email from Insightful Word (IW), a brand of TerraTrance
Technologies, LLC.

Our mailing address: 200 Broadway Blvd NEAlbuquerque, NM 87102



Have a question or need assistance? Reply directly to this email or contact us
[email protected] <mailto:[email protected]>



The content of this email may not be copied, reproduced, forwarded, shared, or
distributed without the prior written consent of TerraTrance Technologies, LLC.

Privacy Policy <[link removed]>
Terms & Conditions <[link removed]>
Unsubscribe
<[link removed]>



© 2026 Insightful Word (IW). All Rights Reserved.